Kellerhals Carrard with Comphya on funding round
Kellerhals Carrard advised Comphya, a medtech spin-off from EPFL Lausanne, throughout closing the second tranche of a CHF 7.5 million Series A financing round.
The context
Comphya will destine the proceeds toward growing the project of an implantable neurostimulation therapy for ED insurged following prostate cancer treatment.
The company has debuted a U.S. pilot study at Johns Hopkins after securing FDA IDE approval earlier this year, and is currently preparing for a U.S. clinical trial planned for 2026.
The Kellerhals Carrard team
The Kellerhals Carrard team working on the matter included partner Karim Maizar (corporate/VC, pictured) and of counsel Joséphine Marmy (corporate/VC).
